Modulacija cirkulirajućih inflamatornih biomarkera SGLT2 inhibitorima kod dijabetičara sa akutnim infarktom miokarda: kvantitativna meta-analiza laboratorijskih dokaza
SGLT2 Inhibitors and Inflammatory Biomarkers in Diabetic AMI
Sažetak
Background: Acute myocardial infarction (AMI) in patients with type 2 diabetes mellitus (T2DM) is characterized by an exaggerated inflammatory response and adverse myocardial remodeling. Sodium–glucose cotransporter-2 inhibitors (SGLT2-I) have demonstrated cardiometabolic benefits; however, their effects on circulating inflammatory biomarkers in diabetic AMI remain inconsistent. This meta-analysis aimed to quantitatively evaluate laboratory-based evidence regarding the modulation of key inflammatory markers by SGLT2-I therapy in this high-risk population.
Methods: A systematic search of PubMed, Embase, Cochrane Library, Web of Science, CNKI, and Wanfang databases was conducted up to December 2025. Randomized controlled trials and prospective cohort studies involving T2DM patients with AMI were included. Primary laboratory endpoints were circulating inflammatory biomarkers (interleukin-6 [IL-6], high-sensitivity C-reactive protein [hs-CRP], tumor necrosis factor-α [TNF-α]). Secondary outcomes included left ventricular ejection fraction (LVEF) and major adverse cardiovascular events (MACE). Data were pooled using fixed- or random-effects models according to heterogeneity. Evidence certainty was assessed using GRADE methodology.
Results: Thirteen studies comprising 2,453 patients were included. SGLT2-I therapy was associated with significant reductions in IL-6 (MD = −2.33, 95% CI: −4.29 to −0.37; p < 0.001) and hs-CRP levels (MD = −1.90, 95% CI: −2.30 to −1.49; p < 0.001), indicating attenuation of systemic inflammatory activity. No statistically significant reduction was observed for TNF-α (MD = −2.66, 95% CI: −6.66 to 1.33; p = 0.19), potentially due to inter-study heterogeneity and limited sample size. Beyond biomarker modulation, SGLT2-I treatment was associated with improved LVEF and reduced MACE risk. Overall evidence quality was graded as moderate.
Conclusions: This meta-analysis provides laboratory-based evidence that SGLT2 inhibitor therapy is associated with significant reductions in circulating IL-6 and hs-CRP levels in diabetic patients with AMI, supporting a potential anti-inflammatory mechanism beyond glucose lowering. These findings highlight the translational relevance of inflammatory biomarkers in evaluating cardiometabolic therapeutic strategies and underscore the need for larger mechanistic studies to further clarify biochemical pathways involved.
Reference
2. Kufazvinei TTJ, Chai J, Boden KA, Channon KM, Choudhury RP. Emerging opportunities to target inflammation: myocardial infarction and type 2 diabetes. Cardiovasc Res 2024; 120(11): 1241-52.
3. Kim YH, Her A, Rha S, Choi CU, Choi BG, Park S, et al. Impact of diabetes and ejection fraction on non-ST-Segment elevation myocardial infarction outcomes. Heart Vessels 2025; 40(11): 991-1004.
4. Matter MA, Paneni F, Libby P, Frantz S, Stähli BE, Templin C, et al. Inflammation in acute myocardial infarction: the good, the bad and the ugly. Eur Heart J 2024; 45(2): 89-103.
5. Yoo TT, Baek IH, Stoletniy L, Hilliard A, Sakr A, Doycheva D. Impact of sodium-glucose transport protein-2 (SGLT2) inhibitors on the inflammasome pathway in acute myocardial infarction in type 2 diabetes mellitus: a comprehensive review. Cardiovasc Diabetol 2025; 24(1): 227.
6. Mukhopadhyay P, Sanyal D, Chatterjee P, Pandit K, Ghosh S. SGLT2 Inhibitors: Effect on Myocardial Infarction and Stroke in Type 2 Diabetes. The Journal of Clinical Endocrinology and Metabolism 2023; 108(8): 2134-40.
7. Preda A, Montecucco F, Carbone F, Camici GG, Lüscher TF, Kraler S, et al. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovasc Res 2024; 120(5): 443-60.
8. Ejiri K, Miyoshi T, Kihara H, Hata Y, Nagano T, Takaishi A, et al. Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure. Sci Rep-Uk 2022; 12(1): 15449.
9. Wang PZ, Cai TF, Tian J, Sang H, Li J, Tian P, Zhang WQ. Effects of sacubitril valsartan sodium combined with dapagliflozin on cardiac function and left ventricular remodeling in patients with acute myocardial infarction and type 2 diabetes mellitus. Chinese Journal of Drug Application and Monitoring 2025; 22: 21-25.
10. Liu CC, Wang YB, Su LF, Zhou Q, Tian J, Hao GZ, Gu XS. Cardiorenal protective effect of dapagliflozin in patients with acute ST-segment elevation myocardial infarction and type 2 diabetes mellitus. Chinese Journal of Evidence-Based Cardiovascular Medicine 2025; 17: 1115-1121.
11. Tang LL. Analysis of the Effects of Dagliflozin on Glucose Metabolism and Cardiac Function after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction and Diabetes Mellitu. Guide of China Medicine 2025; 23: 99-101.
12. Liu K, Chen YY, Chen HY, Xiang XJ, Qiao R, Nie P. Effects of dapagliflozin on glucose metabolism and cardiac function in patients with acute myocardial infarction complicated with diabetes mellitus after percutaneous coronary intervention. Northwest Pharmaceutical Journal 2024; 39: 189-193.
13. Lu YL, Xiao JD, Wang Y, Ma X. Influence of Dapagliflozin on glucose metabolism and cardiac function in elderly patients with ST-segment elevation myocardial infarction complicated with type 2 diabetes mellitus after percutaneous coronary intervention. Chinese Journal of Diabetes 2025; 33: 577-581.
14. Zhao L, Li Z. Effect of dapagliflozin intervention on ventricular remodeling and myocardial microperfusion in patients with acute myocardial infarction complicated with type 2 diabetes mellitus after percutaneous coronary intervention. Shaanxi Medical Journal 2022; 51: 81-83+95.
15. Lin W, Xiong SQ, Zhang P, Zhao L, Li CY, Lin C, Lin FY, Wang T. Clinical trial of daglizin in the treatment of patients with acute myocardial infarction complicated with type 2 diabetes. The Chinese Journal of Clinical Pharmacology 2024; 40: 2924-2928.
16. Qi Y, Yin L, Li J, Zhao J, Wang HR, Xu JH. Effects of empagliflozin on ventricular remodeling and polarization of peripheral blood monocytes after interventional therapy for type 2 diabetes mellitus complicated with acute myocardial infarction. Northwest Pharmaceutical Journal 2025; 40: 165-170.
17. Luo S, Liu H, Li Z, Zhou Y, He S, Zhang D, et al. Effects of SGLT2 Inhibitor in Patients with Diabetes with Newly Diagnosed Acute Myocardial Infarction: A Multicenter Prospective Cohort Study. Cardiovasc Drug Ther 2025: 10-1007.
18. Heshmat A, Wakeel LME, Khorshid H, Fahmy SF. Impact of dapagliflozin administration on remodeling marker and clinical outcomes of stemi patients with diabetes mellitus: a controlled clinical trial. Futur J Pharm Sci 2025; 11: 106.
19. Lv Y, Luo W. Dapagliflozin and sacubitril on myocardial microperfusion in patients with post-acute myocardial infarction heart failure and type 2 diabetes. World J Clin Cases 2024; 12(22): 5008-15.
20. Zhang L, Tang X, Li R, Niu J, Gong J. Efficacy of sacubitril/valsartan combined with dapagliflozin in treating patients with heart failure and diabetes after an acute myocardial infarction. Pak J Med Sci 2024; 40(11): 2464-9.
21. Zhang TC, Bing CY, Li HT. Effect of early application of canagliflozin on cardiac function and prognosis after percutaneous coronary intervention in patients with acute myocardial infarction and type 2 diabetes mellitus. Chinese Journal of Cardiovascular Research 2022; 20: 166-170.
22. Profili NI, Castelli R, Manetti R, Sircana MC, Pagni M, Sechi GL, et al. Sodium-Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction. Biomedicines 2025; 13(3): 720.
23. Xia J, Li B, Zhang H, Li Q, Lam SM, Yin C, et al. Precise Metabolomics Defines Systemic Metabolic Dysregulation Distinct to Acute Myocardial Infarction Associated With Diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology 2023; 43(4): 581-96.
24. Yu Y, Que J, Liu S, Huang K, Qian L, Weng Y, et al. Sodium-Glucose Co-transporter-2 Inhibitor of Dapagliflozin Attenuates Myocardial Ischemia/Reperfusion Injury by Limiting NLRP3 Inflammasome Activation and Modulating Autophagy. Front Cardiovasc Med 2022; 8: 768214.
25. Xu X, Cai L, Chen T, Ding S, Zhang F, Gao B, et al. Predictive value of inflammation-based Glasgow prognostic score, platelet-lymphocyte ratio, and global registry of acute coronary events score for major cardiovascular and cerebrovascular events during hospitalization in patients with acute myocardial infarction. Aging 2021; 13(14): 18274-86.
26. Li Z, Li A, Sun D, Shu Y. Effect of SGLT-2 Inhibitors on Prognosis in Diabetic Patients with Acute Myocardial Infarction: A Systematic Review and Meta-Analysis. Rev Cardiovasc Med 2024; 25(5): 154.
27. Paolisso P, Bergamaschi L, Santulli G, Gallinoro E, Cesaro A, Gragnano F, et al. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Cardiovasc Diabetol 2022; 21(1): 77.
Sva prava zadržana (c) 2026 Jia Xu, Yuanhong Jie, Tao Dong, Qi Li, Xiaobing Liu
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.